
<TR><TD>Z</TD><TD>CYP4 HYDROXYDEBRISOQUINED6 CONTROLS FORMATION OF 4 HYDROXYDEBRISOQUINE</TD><TD>BC SATISFIED ASSERTION_1066, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYPN DESMETHYLSERTRALINEC19 CONTROLS FORMATION OF N DESMETHYLSERTRALINE</TD><TD>BC SATISFIED ASSERTION_960, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZOSUQUIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZOLPIDEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZILEUTON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZALEPLON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ZAFIRLUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VEMURAFENIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VALPROATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TROLEANDOMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIFLUOPERAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIZANIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIPRANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TIGECYCLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIABENDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TENIPOSIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TELAPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAMOXIFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFINPYRAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAPHENAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAMETHIZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SILDENAFIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SAQUINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RANITIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>RABEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINUPRISTIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUININE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOXYPHENE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROMETHAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PRASUGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYLPROPANOLAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAZOPANIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PALIPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXYCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXCARBAZEPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OXANDROLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICARDIPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MOLINDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIFEPRISTONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MICONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METRONIDAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>METHADONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LITHIUM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ISONIAZID IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDOMETHACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ILOPERIDONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>IBUPROFEN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYCHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDRALAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FOSAMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOROURACIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLECAINIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FELBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FEBUXOSTAT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FAMOTIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETRAVIRINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ETHANOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESZOPICLONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESOMEPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELTROMBOPAG IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DROPERIDOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DOXORUBICIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DISULFIRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIPHENHYDRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESLORATADINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DELAVIRDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARUNAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DANAZOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CRIZOTINIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COTRIMOXAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOTRIMAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOMIPRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOBAZAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CINACALCET IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPHENIRAMINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLOROQUINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORAMPHENICOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAPECITABINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BOCEPREVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BICALUTAMIDE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BASILIXIMAB IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AZITHROMYCIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATOMOXETINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ASENAPINE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARMODAFINIL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ARIPIPRAZOLE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMPRENAVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALLOPURINOL IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACYCLOVIR IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R WARFARIN IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM IS AN ACTIVE INGREDIENT</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_831, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_590, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_328, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_406, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_572, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_981, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_333, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1499, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1498, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1221, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1450, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1497, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1420, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1496, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1511, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1494, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1510, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1239, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1493, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1419, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1456, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1446, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1513, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1492, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3</TD><TD>BC SATISFIED ASSERTION_1523, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1462, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1427, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1460, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19</TD><TD>BC SATISFIED ASSERTION_711, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8</TD><TD>BC SATISFIED ASSERTION_1425, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1491, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1459, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1418, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1444, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1443, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1489, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1518, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1441, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1488, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1508, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1442, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1507, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1486, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1423, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1417, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1436, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1452, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_373, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1435, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1434, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1484, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1483, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1451, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1433, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_1426, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6</TD><TD>BC SATISFIED ASSERTION_1422, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1</TD><TD>BC SATISFIED ASSERTION_1504, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1430, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1481, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1416, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1480, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9</TD><TD>BC SATISFIED ASSERTION_309, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6</TD><TD>BC SATISFIED ASSERTION_536, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019, ATORVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021, BETA HYDROXY LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032, CLOZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004, FLUOXETINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004, FLUPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008, FLUVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003, LOVASTATIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C8, MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C19, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153, OLANZAPINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP1A2, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4, PERPHENAZINE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003, RISPERIDONE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6</TD><TD>INHIBITION CONSTANT OF ZIPRASIDONE FOR CYP2D6 IS 0.005, ZIPRASIDONE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2D6, MAXIMUM IN VIVO CONCENTRATION OF ZIPRASIDONE IS 1.0.1294e 4 AT DOSE 0.12, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_832, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_1080, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_687, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_44, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_351, </TD></TR><BR>
<TR><TD>Z</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_727, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_1022, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_349, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1094, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2A6</TD><TD>BC SATISFIED ASSERTION_887, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1172, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_341, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_163, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_899, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_340, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8</TD><TD>BC SATISFIED ASSERTION_745, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_88, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_227, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_582, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2E1</TD><TD>BC SATISFIED ASSERTION_120, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1218, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_119, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_690, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1068, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_834, </TD></TR><BR>
<TR><TD>Z</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_180, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_435, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_789, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_798, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_897, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_758, </TD></TR><BR>
<TR><TD>Z</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_673, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_995, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_702, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4</TD><TD>BC SATISFIED ASSERTION_940, </TD></TR><BR>
<TR><TD>Z</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_946, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_172, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_527, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_198, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_576, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_226, </TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1251, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_444, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_347, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_841, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_814, </TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1010, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6</TD><TD>BC SATISFIED ASSERTION_1253, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9</TD><TD>BC SATISFIED ASSERTION_1050, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19</TD><TD>BC SATISFIED ASSERTION_121, </TD></TR><BR>
<TR><TD>Z</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2</TD><TD>BC SATISFIED ASSERTION_1170, </TD></TR><BR>
<TR><TD>Z</TD><TD>ITRACONAZOLE INHIBITS CYP3A4</TD><TD>ITRACONAZOLE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE INHIBITS CYP2D6</TD><TD>QUINIDINE IS AN IN VIVO SELECTIVE INHIBITOR OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A5</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A5 IS 1.966e 6, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A5, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR P GLYCOPROTEIN IS 0.002817, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF P GLYCOPROTEIN, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_92, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_90, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_680, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_521, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERBINAFINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1205, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1149, </TD></TR><BR>
<TR><TD>Z</TD><TD>TELITHROMYCIN INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_989, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_430, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_64, </TD></TR><BR>
<TR><TD>Z</TD><TD>RITONAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_65, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPAFENONE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_318, </TD></TR><BR>
<TR><TD>Z</TD><TD>PAROXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_1223, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE INHIBITS CYP2C19</TD><TD>BC SATISFIED ASSERTION_1193, </TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_519, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_961, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEFAZODONE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1195, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEXILETINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1155, </TD></TR><BR>
<TR><TD>Z</TD><TD>KETOCONAZOLE INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A4 IS 1.966e 6, KETOCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_485, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_486, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL INHIBITS CYP2C8</TD><TD>BC SATISFIED ASSERTION_876, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_177, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_638, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP3.89e 4A4 IS 3.89e 4, FLUCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE INHIBITS CYP2C9</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP2C9 IS 0.002144, FLUCONAZOLE DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP2C9, MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_714, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4</TD><TD>INHIBITION CONSTANT OF CLARITHROMYCIN FOR CYP0.00168A4 IS 0.00168, CLARITHROMYCIN DOES NOT PERMANENTLY DEACTIVATE CATALYTIC FUNCTION OF CYP3A4, MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5, ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_313, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_1102, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_1103, </TD></TR><BR>
<TR><TD>Z</TD><TD>CIMETIDINE INHIBITS CYP1A2</TD><TD>BC SATISFIED ASSERTION_1071, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_854, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A5</TD><TD>BC SATISFIED ASSERTION_241, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATAZANAVIR INHIBITS CYP3A4</TD><TD>BC SATISFIED ASSERTION_242, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2D6</TD><TD>BC SATISFIED ASSERTION_404, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMIODARONE INHIBITS CYP2C9</TD><TD>BC SATISFIED ASSERTION_403, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>AMIODARONE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ATAZANAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>ATAZANAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIMETIDINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CIMETIDINE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CIMETIDINE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>CLARITHROMYCIN INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUCONAZOLE INHIBITS CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>FLUCONAZOLE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>GEMFIBROZIL INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>INDINAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>INDINAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>KETOCONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MEXILETINE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>NEFAZODONE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>NEFAZODONE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>NORFLOXACIN INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OMEPRAZOLE INHIBITS CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PROPAFENONE INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>RITONAVIR INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>RITONAVIR INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TELITHROMYCIN INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>TELITHROMYCIN INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VERAPAMIL INHIBITS CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VERAPAMIL INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>VERAPAMIL INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>ITRACONAZOLE INHIBITS CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALPRAZOLAM VIA CYP3A5</TD><TD>KETOCONAZOLE INHIBITS CYP3A5, ALPRAZOLAM IS SUBSTRATE OF CYP3A5, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-1</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN, TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>AMIODARONE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>AMIODARONE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ATAZANAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ATAZANAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>BUPROPION INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BUPROPION INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIMETIDINE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CIMETIDINE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CIPROFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>CIPROFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>CLARITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>CLARITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF S WARFARIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF CELECOXIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF PHENYTOIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP2C9 THE PRIMARY TOTAL CLEARANCE ENZ OF TOLBUTAMIDE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9, PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>FLUCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>FLUOXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>FLUOXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>GEMFIBROZIL INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF PACLITAXEL</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>GEMFIBROZIL INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>GEMFIBROZIL INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>INDINAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>INDINAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>MEXILETINE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>MEXILETINE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NEFAZODONE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>NEFAZODONE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>NORFLOXACIN INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>NORFLOXACIN INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>OMEPRAZOLE INHIBITS CYP2C19 THE PRIMARY TOTAL CLEARANCE ENZ OF PANTOPRAZOLE</TD><TD>OMEPRAZOLE INHIBITS METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19, PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PAROXETINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>PAROXETINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>PROPAFENONE INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>PROPAFENONE INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>RITONAVIR INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>RITONAVIR INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>SERTRALINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>SERTRALINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TELITHROMYCIN INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>TELITHROMYCIN INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TERBINAFINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>TERBINAFINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF PACLITAXEL</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>TRIMETHOPRIM INHIBITS CYP2C8 THE PRIMARY TOTAL CLEARANCE ENZ OF ROSIGLITAZONE</TD><TD>TRIMETHOPRIM INHIBITS METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8, PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF ALOSETRON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF DULOXETINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF MELATONIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF RAMELTEON</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP1A2 THE PRIMARY TOTAL CLEARANCE ENZ OF TACRINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TACRINE VIA CYP1A2, PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>VERAPAMIL INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>VERAPAMIL INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF APREPITANT</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CONIVAPTAN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF CYCLOSPORINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DARIFENACIN</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DASATINIB</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DIHYDROERGOTAMINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF DRONEDARONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF FLUTICASONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF INDINAVIR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF LURASIDONE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF MARAVIROC</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUETIAPINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF QUINIDINE</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>ITRACONAZOLE INHIBITS CYP3A4 THE PRIMARY TOTAL CLEARANCE ENZ OF TICAGRELOR</TD><TD>ITRACONAZOLE INHIBITS METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4, PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF NEBIVOLOL</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PIMOZIDE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF PERPHENAZINE</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF DESACETYLDILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>QUINIDINE INHIBITS CYP2D6 THE PRIMARY TOTAL CLEARANCE ENZ OF N DEMETHYLDESACETYL DILTIAZEM</TD><TD>QUINIDINE INHIBITS METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6, PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF ALISKIREN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF ALISKIREN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF AMBRISENTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF AMBRISENTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF DABIGATRAN ETEXILATE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF DABIGATRAN ETEXILATE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF EVEROLIMUS</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF EVEROLIMUS VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF IMATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF IMATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF LAPATINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF LAPATINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF NILOTINIB</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF NILOTINIB VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF POSACONAZOLE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF POSACONAZOLE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF RANOLAZINE</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF RANOLAZINE VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SAXAGLIPTIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SAXAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF SITAGLIPTIN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF SITAGLIPTIN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TALINOLOL</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TALINOLOL VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOLVAPTAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOLVAPTAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>PKI-3</TD><TD>KETOCONAZOLE INHIBITS P GLYCOPROTEIN THE PRIMARY TOTAL CLEARANCE ENZ OF TOPOTECAN</TD><TD>KETOCONAZOLE INHIBITS METABOLIC CLEARANCE OF TOPOTECAN VIA P GLYCOPROTEIN, PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_1233, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.2</TD><TD>BC SATISFIED ASSERTION_482, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF VALPROATE IS 0.5</TD><TD>BC SATISFIED ASSERTION_889, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_197, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.025</TD><TD>BC SATISFIED ASSERTION_477, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 0.25</TD><TD>BC SATISFIED ASSERTION_983, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 0.84</TD><TD>BC SATISFIED ASSERTION_794, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 1.0</TD><TD>BC SATISFIED ASSERTION_185, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.065</TD><TD>BC SATISFIED ASSERTION_1033, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.0125</TD><TD>BC SATISFIED ASSERTION_998, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.02</TD><TD>BC SATISFIED ASSERTION_622, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.06</TD><TD>BC SATISFIED ASSERTION_754, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.03</TD><TD>BC SATISFIED ASSERTION_23, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 0.75</TD><TD>BC SATISFIED ASSERTION_429, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.01</TD><TD>BC SATISFIED ASSERTION_1208, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.015</TD><TD>BC SATISFIED ASSERTION_1060, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.02</TD><TD>BC SATISFIED ASSERTION_935, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.2</TD><TD>BC SATISFIED ASSERTION_589, </TD></TR><BR>
<TR><TD>Z</TD><TD>MINIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.01</TD><TD>BC SATISFIED ASSERTION_368, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ZAFIRLUKAST IS 0.04</TD><TD>BC SATISFIED ASSERTION_512, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VORICONAZOLE IS 0.6</TD><TD>BC SATISFIED ASSERTION_599, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF VALPROATE IS 4.2</TD><TD>BC SATISFIED ASSERTION_317, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TRIMETHOPRIM IS 0.2</TD><TD>BC SATISFIED ASSERTION_214, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOPIRAMATE IS 0.4</TD><TD>BC SATISFIED ASSERTION_1131, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF TOLBUTAMIDE IS 3.0</TD><TD>BC SATISFIED ASSERTION_4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF THEOPHYLLINE IS 1.05</TD><TD>BC SATISFIED ASSERTION_647, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF RANOLAZINE IS 2.0</TD><TD>BC SATISFIED ASSERTION_505, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROPOXYPHENE IS 0.6</TD><TD>BC SATISFIED ASSERTION_307, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PROMETHAZINE IS 0.15</TD><TD>BC SATISFIED ASSERTION_1150, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF PANTOPRAZOLE IS 0.24</TD><TD>BC SATISFIED ASSERTION_738, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF NICARDIPINE IS 0.12</TD><TD>BC SATISFIED ASSERTION_135, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF MIDODRINE IS 0.04</TD><TD>BC SATISFIED ASSERTION_186, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF METRONIDAZOLE IS 4.0</TD><TD>BC SATISFIED ASSERTION_164, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LEFLUNOMIDE IS 0.2</TD><TD>BC SATISFIED ASSERTION_924, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF LANSOPRAZOLE IS 0.18</TD><TD>BC SATISFIED ASSERTION_1008, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF FLUVASTATIN IS 0.8</TD><TD>BC SATISFIED ASSERTION_25, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF CELECOXIB IS 0.8</TD><TD>BC SATISFIED ASSERTION_967, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM THERAPEUTIC DOSE OF ATORVASTATIN IS 0.08</TD><TD>BC SATISFIED ASSERTION_1089, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZOSUQUIDAR FOR P GLYCOPROTEIN IS 1.529e 5</TD><TD>BC SATISFIED ASSERTION_1637, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ZIPRASIDONE FOR CYP2D6 IS 0.005</TD><TD>BC SATISFIED ASSERTION_154, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR P GLYCOPROTEIN IS 0.003637</TD><TD>BC SATISFIED ASSERTION_1642, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A5 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1583, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VERAPAMIL FOR CYP0.004546A4 IS 0.004546</TD><TD>BC SATISFIED ASSERTION_1579, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF VALSPODAR FOR P GLYCOPROTEIN IS 1.336e 4</TD><TD>BC SATISFIED ASSERTION_1641, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRYPTAMINE FOR CYP2A6 IS 0.001643</TD><TD>BC SATISFIED ASSERTION_1536, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A5 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1582, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TROLEANDOMYCIN FOR CYP2.198e 4A4 IS 2.198e 4</TD><TD>BC SATISFIED ASSERTION_1578, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRIMETHOPRIM FOR CYP2C8 IS 0.00929</TD><TD>BC SATISFIED ASSERTION_1556, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TRANYLCYPROMINE FOR CYP2A6 IS 2.664e 6</TD><TD>BC SATISFIED ASSERTION_1533, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2C19 IS 3.165e 4</TD><TD>BC SATISFIED ASSERTION_1020, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF TICLOPIDINE FOR CYP2B6 IS 5.276e 5</TD><TD>BC SATISFIED ASSERTION_352, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTHIXENE FOR CYP2D6 IS 0.029</TD><TD>BC SATISFIED ASSERTION_293, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIOTEPA FOR CYP2B6 IS 9.082e 4</TD><TD>BC SATISFIED ASSERTION_1548, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF THIORIDAZINE FOR CYP2D6 IS 5.699e 4</TD><TD>BC SATISFIED ASSERTION_1230, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SULFAPHENAZOLE FOR CYP2C9 IS 4.087e 4</TD><TD>BC SATISFIED ASSERTION_1562, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SIMVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_256, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF SERTRALINE FOR CYP2B6 IS 9.799e 4</TD><TD>BC SATISFIED ASSERTION_1546, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ROSIGLITAZONE FOR CYP2C8 IS 0.002002</TD><TD>BC SATISFIED ASSERTION_767, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RISPERIDONE FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_625, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF RESERPINE FOR P GLYCOPROTEIN IS 8.522e 4</TD><TD>BC SATISFIED ASSERTION_1644, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR P GLYCOPROTEIN IS 7.137e 4</TD><TD>BC SATISFIED ASSERTION_1639, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUINIDINE FOR CYP2D6 IS 8.759e 5</TD><TD>BC SATISFIED ASSERTION_1569, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF QUERCETIN FOR CYP2C8 IS 0.001871</TD><TD>BC SATISFIED ASSERTION_1555, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PIOGLITAZONE FOR CYP2C8 IS 6.059e 4</TD><TD>BC SATISFIED ASSERTION_636, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PILOCARPINE FOR CYP2A6 IS 8.33e 4</TD><TD>BC SATISFIED ASSERTION_1535, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PHENCYCLIDINE FOR CYP2B6 IS 0.002434</TD><TD>BC SATISFIED ASSERTION_1547, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP2D6 IS 3.2e 4</TD><TD>BC SATISFIED ASSERTION_569, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PERPHENAZINE FOR CYP1A2 IS 0.026</TD><TD>BC SATISFIED ASSERTION_144, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF PALIPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_442, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP0.153A4 IS 0.153</TD><TD>BC SATISFIED ASSERTION_749, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C9 IS 0.223</TD><TD>BC SATISFIED ASSERTION_446, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF OLANZAPINE FOR CYP2C19 IS 0.287</TD><TD>BC SATISFIED ASSERTION_824, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NORFLUOXETINE FOR CYP4.252e 4A4 IS 4.252e 4</TD><TD>BC SATISFIED ASSERTION_613, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NOOTKATONE FOR CYP2C19 IS 1.092e 4</TD><TD>BC SATISFIED ASSERTION_1568, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF NELFINAVIR FOR P GLYCOPROTEIN IS 7.949e 4</TD><TD>BC SATISFIED ASSERTION_1638, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF MONTELUKAST FOR CYP2C8 IS 6.448e 4</TD><TD>BC SATISFIED ASSERTION_542, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF METHOXSALEN FOR CYP2A6 IS 2.162e 6</TD><TD>BC SATISFIED ASSERTION_1534, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF LOVASTATIN FOR CYP2C8 IS 0.003</TD><TD>BC SATISFIED ASSERTION_118, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR P GLYCOPROTEIN IS 0.002817</TD><TD>BC SATISFIED ASSERTION_1636, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A5 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_1580, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF KETOCONAZOLE FOR CYP1.966e 6A4 IS 1.966e 6</TD><TD>BC SATISFIED ASSERTION_859, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.905e 4A5 IS 1.905e 4</TD><TD>BC SATISFIED ASSERTION_1581, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ITRACONAZOLE FOR CYP1.905e 4A4 IS 1.905e 4</TD><TD>BC SATISFIED ASSERTION_943, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF HALOPERIDOL FOR CYP2D6 IS 0.003</TD><TD>BC SATISFIED ASSERTION_676, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF GEMFIBROZIL FOR CYP2C8 IS 0.01727</TD><TD>BC SATISFIED ASSERTION_1557, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FURAFYLLINE FOR CYP1A2 IS 1.562e 4</TD><TD>BC SATISFIED ASSERTION_1527, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP2C9 IS 0.002037</TD><TD>BC SATISFIED ASSERTION_1564, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVOXAMINE FOR CYP1A2 IS 2.072e 5</TD><TD>BC SATISFIED ASSERTION_316, THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUVASTATIN FOR CYP2C8 IS 0.008</TD><TD>BC SATISFIED ASSERTION_1105, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP2D6 IS 0.004</TD><TD>BC SATISFIED ASSERTION_421, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUPHENAZINE FOR CYP1A2 IS 0.018</TD><TD>BC SATISFIED ASSERTION_322, PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP0.004A4 IS 0.004</TD><TD>BC SATISFIED ASSERTION_725, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUOXETINE FOR CYP2C9 IS 0.005568</TD><TD>BC SATISFIED ASSERTION_1565, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP3.89e 4A4 IS 3.89e 4</TD><TD>BC SATISFIED ASSERTION_560, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF FLUCONAZOLE FOR CYP2C9 IS 0.002144</TD><TD>BC SATISFIED ASSERTION_1563, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ERYTHROMYCIN FOR CYP0.006A4 IS 0.006</TD><TD>BC SATISFIED ASSERTION_643, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ELACRIDAR FOR P GLYCOPROTEIN IS 2.255e 4</TD><TD>BC SATISFIED ASSERTION_1643, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DILTIAZEM FOR CYP2.2e 4A4 IS 2.2e 4</TD><TD>BC SATISFIED ASSERTION_416, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF DIETHYLDITHIOCARBAMATE FOR CYP2E1 IS 0.00214</TD><TD>BC SATISFIED ASSERTION_1571, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYCLOSPORINE FOR P GLYCOPROTEIN IS 6.013e 4</TD><TD>BC SATISFIED ASSERTION_1635, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP0.032A4 IS 0.032</TD><TD>BC SATISFIED ASSERTION_781, MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2D6 IS 0.013</TD><TD>BC SATISFIED ASSERTION_448, DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C9 IS 0.01</TD><TD>BC SATISFIED ASSERTION_785, TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOZAPINE FOR CYP2C19 IS 0.023</TD><TD>BC SATISFIED ASSERTION_677, S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLOPIDOGREL FOR CYP2B6 IS 1.609e 4</TD><TD>BC SATISFIED ASSERTION_453, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CLARITHROMYCIN FOR CYP0.00168A4 IS 0.00168</TD><TD>BC SATISFIED ASSERTION_41, TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY SIMVASTATIN FOR CYP2C8 IS 0.018</TD><TD>BC SATISFIED ASSERTION_869, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF BETA HYDROXY LOVASTATIN FOR CYP2C8 IS 0.021</TD><TD>BC SATISFIED ASSERTION_566, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ATORVASTATIN FOR CYP2C8 IS 0.019</TD><TD>BC SATISFIED ASSERTION_770, PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF ALPHA NAPHTHOFLAVONE FOR CYP1A2 IS 2.723e 5</TD><TD>BC SATISFIED ASSERTION_1528, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF 9 HYDROXYRISPERIDONE FOR CYP2D6 IS 0.007</TD><TD>BC SATISFIED ASSERTION_142, BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>INHIBITION CONSTANT OF CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE FOR CYP2B6 IS 0.001009</TD><TD>BC SATISFIED ASSERTION_1545, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALISKIREN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALOSETRON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMBRISENTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>APREPITANT IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATRASENTAN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>CELECOXIB IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>CONIVAPTAN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>DABIGATRAN ETEXILATE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>DARIFENACIN IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DASATINIB IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DRONEDARONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>DULOXETINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ IS SUBSTRATE OF CYP2B6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>EVEROLIMUS IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>EZETIMIBE IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUTICASONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>IMATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>INDINAVIR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>IRINOTECAN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAPATINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>LURASIDONE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MARAVIROC IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MELATONIN IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>NEBIVOLOL IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>NILOTINIB IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS SUBSTRATE OF CYP2C8</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PANTOPRAZOLE IS SUBSTRATE OF CYP2C19</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIMOZIDE IS SUBSTRATE OF CYP2D6</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PITAVASTATIN IS SUBSTRATE OF OATP1B3</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3, </TD></TR><BR>
<TR><TD>Z</TD><TD>POSACONAZOLE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRAVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>RAMELTEON IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>RANOLAZINE IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS SUBSTRATE OF CYP2C8</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSUVASTATIN IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>SAXAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS SUBSTRATE OF OATP1B1</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>SITAGLIPTIN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE IS SUBSTRATE OF CYP1A2</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICAGRELOR IS SUBSTRATE OF CYP3A4</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS SUBSTRATE OF CYP2C9</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLVAPTAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOPOTECAN IS SUBSTRATE OF P GLYCOPROTEIN</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_494, CYP2C19 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_480, DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PERPHENAZINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_577, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUVOXAMINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_780, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_802, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_9, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>ALPRAZOLAM IS SUBSTRATE OF CYP3A5</TD><TD>BC SATISFIED ASSERTION_98, </TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_611, CYP2D6 IS A POLYMORPHIC ENZYME, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM PERMANENTLY DEACTIVATES CATALYTIC FUNCTION OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_259, </TD></TR><BR>
<TR><TD>Z</TD><TD>ZIPRASIDONE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>VORICONAZOLE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THREOHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE 5 SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE 6B HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERIFLUNOMIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE PARA HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>REDUCED HALOPERIDOL IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE SULFOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORPROPOXYPHENE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NORFLUOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MODAFINIL SULFONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXYBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROXY HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>HYDROCINNAMIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE O DEALKYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROHYDROBUPROPION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DICLOFENAC 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESMETHYLCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESGLYMIDODRINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DESACETYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEHYDRO ARIPIPRAZOLE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL 1’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHOXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>BENZISOTHIAZOLE SULPHONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA NAPHTHOFLAVONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ALPHA HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S ZOPICLONE N OXIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN 7 HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S METHYL DIHYDROZIPRASIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4’ HYDROXYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>S N DESMETHYLZOPICLONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DIDEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>R DEMETHYLCITALOPRAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>O DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLVENLAFAXINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLTAMOXIFEN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLSERTRALINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESMETHYLATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DESALKYLQUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYLDESACETYL DILTIAZEM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>N DEMETHYL_ERYTHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>M CHLOROPHENYLPIPERAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>9 HYDROXYRISPERIDONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYPERPHENAZINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXYCLOZAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 HYDROXY N DESALKYL QUETIAPINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXYMETHYL SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME HYDROXY SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE SIMVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME EXOMETHYLENE LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6PRIME BETA HYDROXY LOVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>6BETA HYDROXYTESTOSTERONE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTRIAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYTAMOXIFIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYDEBRISOQUINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYATOMOXETINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 HYDROXYALPRAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3ALPHA HYDROXYPRAVASTATIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>3 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>2 ISOPROPENYL 2 METHYL ADAMANTANE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1PRIME HYDROXYMIDAZOLAM IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>14 HYDROXYCLARITHROMYCIN IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>10 N GLUCURONIDE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLXANTHINE IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1 METHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>1,3 DIMETHYLURIC ACID IS A METABOLITE</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>SIMVASTATIN IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>MIDODRINE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>LEFLUNOMIDE IS A PRODRUG</TD><TD></TD></TR><BR>
<TR><TD>Z</TD><TD>ACCEPT IN VITRO BASED ENZYME MODULATION ASSERTIONS</TD><TD></TD></TR><BR>
<TR><TD>(BC-SATISFIED 'ASSERTION_950)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_934)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_928)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_914)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_91)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_909)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_893)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_822)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_821)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_800)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_769)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_752)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_740)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_736)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_728)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_720)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_708)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_703)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_70)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_689)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_686)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_568)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_503)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_472)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_45)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_440)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_409)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_396)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_354)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_344)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_33)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_314)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_30)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_240)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_206)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_176)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_138)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1298)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1297)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1296)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1295)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1292)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_129)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1288)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1287)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1286)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1285)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1284)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1281)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1279)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1277)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1273)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1266)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1243)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1217)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1215)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1212)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1171)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_116)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1157)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1106)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_110)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1087)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1078)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_107)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1067)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1053)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1007)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1003)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_250)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1074)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1034)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_438)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_645)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_10)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1499)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1498)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1221)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1450)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1497)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1496)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1511)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1510)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1239)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1493)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1419)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1456)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1513)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1492)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1523)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1462)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1427)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1460)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_711)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1425)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1491)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1459)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1418)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1444)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1443)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1489)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1441)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1488)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1508)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1507)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1486)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1417)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1436)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1452)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_373)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1434)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1484)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1483)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1451)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1422)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1504)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1430)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1481)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_309)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1047)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1233)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_482)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_889)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_197)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_477)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_983)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_794)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_185)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1033)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_998)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_754)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_23)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_429)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1208)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1060)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_935)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_368)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_512)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_599)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_317)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_214)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_4)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_647)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_505)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_307)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1150)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_738)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_135)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_186)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_164)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_924)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1008)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_25)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_967)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1089)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_813)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_698)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_275)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_867)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_884)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_267)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_464)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_605)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_466)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1219)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1232)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_655)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1017)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_104)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1179)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_806)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_844)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1023)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_514)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1085)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_518)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_455)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_921)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_131)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_153)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_788)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_423)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_629)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_224)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_865)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_312)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_942)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_101)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1148)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_741)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_49)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_880)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1126)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_154)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1642)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1583)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1579)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1641)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1536)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1578)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1556)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1533)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1020)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_352)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_293)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1548)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1230)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1562)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_256)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1546)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_767)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1644)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1639)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1555)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_636)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1547)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_569)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_144)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_442)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_749)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_446)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_824)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1568)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1638)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_542)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1534)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_118)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1636)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1580)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_859)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_943)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_676)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1557)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1564)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_316)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1105)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_421)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_322)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_725)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1565)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_560)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1563)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_643)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1643)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_416)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1571)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_781)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_448)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_785)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_677)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_453)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_41)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_869)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_566)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_770)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1528)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_142)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1545)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_694)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_912)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1025)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_666)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_495)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1091)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_151)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_290)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_66)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_846)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_348)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_762)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_678)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_581)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_674)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_894)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_420)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_467)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1220)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_664)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1162)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_402)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_8)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1063)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_637)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_494)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_480)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_577)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_780)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_802)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_9)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_98)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_669)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1632)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1631)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1532)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1551)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1529)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1543)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1541)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1190)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1558)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1539)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1553)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1634)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1550)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1554)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1531)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1540)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1567)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1628)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1549)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1530)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1552)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1561)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1559)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1633)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1570)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1625)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1542)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1573)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1538)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1617)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_905)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1598)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_815)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1586)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_311)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_437)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1618)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1595)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1624)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1588)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1622)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1593)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1602)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1584)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_278)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_692)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1610)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_948)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1604)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1134)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1619)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1590)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1613)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_565)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1611)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1601)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1615)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_346)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1591)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1607)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1616)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_61)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1608)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_842)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1589)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_561)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1609)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_426)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1587)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1592)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_744)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1612)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1596)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_234)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1594)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1603)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_607)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1585)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_399)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_831)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_590)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_328)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_406)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_572)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_981)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_333)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_468)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_294)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_658)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_102)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_433)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1211)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_424)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_92)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_90)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_680)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_521)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1205)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1149)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_989)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_430)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_64)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_65)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_318)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1223)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1193)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_519)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_961)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1195)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1155)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_630)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_485)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_486)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_876)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_177)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_638)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_201)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_29)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_111)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_764)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_371)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_714)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_713)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_313)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1057)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1102)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1103)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1071)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_388)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_854)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1015)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_241)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_242)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_404)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_403)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_735)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_305)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_635)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_766)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_850)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1252)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1006)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1042)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1100)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1259)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_848)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_978)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_971)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_289)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_901)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_46)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_535)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_476)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_540)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_801)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_496)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_847)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_122)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1099)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_653)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_832)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1080)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_687)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_44)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_351)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_727)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1022)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_349)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1094)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_887)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_341)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_163)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1222)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_899)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_340)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_745)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_88)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_227)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_582)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_120)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1218)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_119)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_690)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1068)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_834)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_180)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_435)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_789)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_798)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_897)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_758)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_673)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_995)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_702)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_940)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_946)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_172)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_133)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_527)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_198)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_576)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_226)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1251)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_444)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_347)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_841)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_814)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1010)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1253)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1050)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_121)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1170)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_1066)</TD></TR>
<TR><TD>(BC-SATISFIED 'ASSERTION_960)</TD></TR>
<TR><TD>Z</TD><TD>TRIAZOLAM 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1617, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_905, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE METHYL HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1598, </TD></TR><BR>
<TR><TD>Z</TD><TD>TOLBUTAMIDE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_815, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1586, </TD></TR><BR>
<TR><TD>Z</TD><TD>THEOPHYLLINE IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_311, </TD></TR><BR>
<TR><TD>Z</TD><TD>TESTOSTERONE IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_437, </TD></TR><BR>
<TR><TD>Z</TD><TD>TERFENADINE C HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1618, </TD></TR><BR>
<TR><TD>Z</TD><TD>TAXOL 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1595, </TD></TR><BR>
<TR><TD>Z</TD><TD>TALINOLOL IS AN IN VITRO PROBE SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1624, </TD></TR><BR>
<TR><TD>Z</TD><TD>TACRINE 1 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1588, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUINIDINE IS AN IN VITRO PROBE SUBSTRATE OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1622, </TD></TR><BR>
<TR><TD>Z</TD><TD>PROPOFOL HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1593, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENYTOIN 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1602, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN O DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1584, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENACETIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_278, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL 3 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1610, </TD></TR><BR>
<TR><TD>Z</TD><TD>P NITROPHENOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_948, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE 5 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1604, </TD></TR><BR>
<TR><TD>Z</TD><TD>OMEPRAZOLE IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1134, </TD></TR><BR>
<TR><TD>Z</TD><TD>NIFEDIPINE OXIDATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1619, </TD></TR><BR>
<TR><TD>Z</TD><TD>NICOTINE C OXIDATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1590, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM 1 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1613, </TD></TR><BR>
<TR><TD>Z</TD><TD>MIDAZOLAM IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_565, </TD></TR><BR>
<TR><TD>Z</TD><TD>LAURIC ACID 11 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1611, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLURBIPROFEN 4’ HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1601, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1615, </TD></TR><BR>
<TR><TD>Z</TD><TD>ERYTHROMYCIN IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_346, </TD></TR><BR>
<TR><TD>Z</TD><TD>EFAVIRENZ HYDROXYLASE IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1591, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN O DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1607, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1616, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_61, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_1608, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_842, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN 7 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1589, </TD></TR><BR>
<TR><TD>Z</TD><TD>COUMARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_561, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE 6 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1609, </TD></TR><BR>
<TR><TD>Z</TD><TD>CHLORZOXAZONE IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_426, </TD></TR><BR>
<TR><TD>Z</TD><TD>CAFFEINE 3 N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1587, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUPROPION HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1592, </TD></TR><BR>
<TR><TD>Z</TD><TD>BUFURALOL IS AN IN VITRO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_744, </TD></TR><BR>
<TR><TD>Z</TD><TD>ANILINE 4 HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1612, </TD></TR><BR>
<TR><TD>Z</TD><TD>AMODIAQUINE N DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1596, </TD></TR><BR>
<TR><TD>Z</TD><TD>S WARFARIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_234, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN N DEMETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1594, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN 4’ HYDROXYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1603, </TD></TR><BR>
<TR><TD>Z</TD><TD>S MEPHENYTOIN IS AN IN VITRO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_607, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN O DEETHYLATION IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_1585, </TD></TR><BR>
<TR><TD>Z</TD><TD>7 ETHOXYRESORUFIN IS AN IN VITRO PROBE SUBSTRATE OF CYP1A2</TD><TD>BC SATISFIED ASSERTION_399, </TD></TR><BR>
<TR><TD>Z</TD><TD>PACLITAXEL IS AN IN VITRO PROBE SUBSTRATE OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_692, </TD></TR><BR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '2-ISOPROPENYL-2-METHYL-ADAMANTANE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         '9-HYDROXYRISPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ALPHA-NAPHTHOFLAVONE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOPIDOGREL
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'CLOZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CYCLOSPORINE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'DIETHYLDITHIOCARBAMATE 'CYP2E1)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ELACRIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUCONAZOLE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUOXETINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'FLUPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVOXAMINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FURAFYLLINE
         'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'GEMFIBROZIL
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'HALOPERIDOL
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ITRACONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'KETOCONAZOLE 'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'METHOXSALEN
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'MONTELUKAST
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NELFINAVIR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'NOOTKATONE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'NORFLUOXETINE 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'OLANZAPINE
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PALIPERIDONE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP1A2)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PERPHENAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PHENCYCLIDINE 'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'PILOCARPINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'PIOGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUERCETIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'QUINIDINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RESERPINE
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'RISPERIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ROSIGLITAZONE 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SERTRALINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'SULFAPHENAZOLE 'CYP2C9)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'THIORIDAZINE 'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTEPA
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'THIOTHIXENE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2B6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TICLOPIDINE
         'CYP2C19)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRANYLCYPROMINE 'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TRIMETHOPRIM 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'TROLEANDOMYCIN 'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'TRYPTAMINE
         'CYP2A6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VALSPODAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'CYP3A5)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'VERAPAMIL
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZIPRASIDONE
         'CYP2D6)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'ZOSUQUIDAR
         'P-GLYCOPROTEIN)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'SIMVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'LOVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2 'FLUVASTATIN
         'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ERYTHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'CLARITHROMYCIN 'CYP3A4)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-SIMVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'BETA-HYDROXY-LOVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>(1-DOES-NOT-PERMANENTLY-DEACTIVATE-CATALYTIC-FUNCTION-OF-2
         'ATORVASTATIN 'CYP2C8)</TD></TR>
<TR><TD>Z</TD><TD>VENLAFAXINE HAS METABOLITE O DESMETHYLVENLAFAXINE</TD><TD>BC SATISFIED ASSERTION_735, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE THIORIDAZINE 5 SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_305, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIORIDAZINE HAS METABOLITE MESORIDAZINE</TD><TD>BC SATISFIED ASSERTION_635, </TD></TR><BR>
<TR><TD>Z</TD><TD>RISPERIDONE HAS METABOLITE 9 HYDROXYRISPERIDONE</TD><TD>BC SATISFIED ASSERTION_766, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE QUETIAPINE SULFOXIDE</TD><TD>BC SATISFIED ASSERTION_850, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1252, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUETIAPINE HAS METABOLITE 7 HYDROXY N DESALKYL QUETIAPINE</TD><TD>BC SATISFIED ASSERTION_1006, </TD></TR><BR>
<TR><TD>Z</TD><TD>OLANZAPINE HAS METABOLITE 10 N GLUCURONIDE</TD><TD>BC SATISFIED ASSERTION_1042, </TD></TR><BR>
<TR><TD>Z</TD><TD>HALOPERIDOL HAS METABOLITE REDUCED HALOPERIDOL</TD><TD>BC SATISFIED ASSERTION_1100, DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE DESACETYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_1259, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDILTIAZEM</TD><TD>BC SATISFIED ASSERTION_848, </TD></TR><BR>
<TR><TD>Z</TD><TD>DILTIAZEM HAS METABOLITE N DEMETHYLDESACETYL DILTIAZEM</TD><TD>BC SATISFIED ASSERTION_978, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE DESMETHYLCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_971, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE CLOZAPINE N OXIDE</TD><TD>BC SATISFIED ASSERTION_289, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOZAPINE HAS METABOLITE 7 HYDROXYCLOZAPINE</TD><TD>BC SATISFIED ASSERTION_901, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE PARA HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_46, </TD></TR><BR>
<TR><TD>Z</TD><TD>ATORVASTATIN HAS METABOLITE ORTHO HYDROXY ATORVASTATIN</TD><TD>BC SATISFIED ASSERTION_535, </TD></TR><BR>
<TR><TD>Z</TD><TD>MEPHENYTOIN IS AN IN VIVO PROBE SUBSTRATE OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_468, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEXTROMETHORPHAN IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_294, </TD></TR><BR>
<TR><TD>Z</TD><TD>DEBRISOQUINE IS AN IN VIVO PROBE SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_658, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP3A4 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_102, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2D6 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_433, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C9 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_1211, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2C19 IS A POLYMORPHIC ENZYME</TD><TD>BC SATISFIED ASSERTION_424, </TD></TR><BR>
<TR><TD>Z</TD><TD>VERAPAMIL IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1632, </TD></TR><BR>
<TR><TD>Z</TD><TD>VALSPODAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1631, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRYPTAMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1532, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRIMETHOPRIM IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1551, </TD></TR><BR>
<TR><TD>Z</TD><TD>TRANYLCYPROMINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1529, </TD></TR><BR>
<TR><TD>Z</TD><TD>TICLOPIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1543, </TD></TR><BR>
<TR><TD>Z</TD><TD>THIOTEPA IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1541, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULPHAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1190, </TD></TR><BR>
<TR><TD>Z</TD><TD>SULFAPHENAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1558, </TD></TR><BR>
<TR><TD>Z</TD><TD>SERTRALINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1539, </TD></TR><BR>
<TR><TD>Z</TD><TD>ROSIGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1553, </TD></TR><BR>
<TR><TD>Z</TD><TD>RESERPINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1634, </TD></TR><BR>
<TR><TD>Z</TD><TD>QUERCETIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1550, </TD></TR><BR>
<TR><TD>Z</TD><TD>PIOGLITAZONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1554, </TD></TR><BR>
<TR><TD>Z</TD><TD>PILOCARPINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1531, </TD></TR><BR>
<TR><TD>Z</TD><TD>PHENCYCLIDINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1540, </TD></TR><BR>
<TR><TD>Z</TD><TD>NOOTKATONE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C19</TD><TD>BC SATISFIED ASSERTION_1567, </TD></TR><BR>
<TR><TD>Z</TD><TD>NELFINAVIR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1628, </TD></TR><BR>
<TR><TD>Z</TD><TD>MONTELUKAST IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1549, </TD></TR><BR>
<TR><TD>Z</TD><TD>METHOXSALEN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2A6</TD><TD>BC SATISFIED ASSERTION_1530, </TD></TR><BR>
<TR><TD>Z</TD><TD>GEMFIBROZIL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C8</TD><TD>BC SATISFIED ASSERTION_1552, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUOXETINE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1561, </TD></TR><BR>
<TR><TD>Z</TD><TD>FLUCONAZOLE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2C9</TD><TD>BC SATISFIED ASSERTION_1559, </TD></TR><BR>
<TR><TD>Z</TD><TD>ELACRIDAR IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1633, </TD></TR><BR>
<TR><TD>Z</TD><TD>DIETHYLDITHIOCARBAMATE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2E1</TD><TD>BC SATISFIED ASSERTION_1570, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYCLOSPORINE IS AN IN VITRO SELECTIVE INHIBITOR OF P GLYCOPROTEIN</TD><TD>BC SATISFIED ASSERTION_1625, </TD></TR><BR>
<TR><TD>Z</TD><TD>CLOPIDOGREL IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1542, </TD></TR><BR>
<TR><TD>Z</TD><TD>AZAMULIN IS AN IN VITRO SELECTIVE INHIBITOR OF CYP3A4</TD><TD>BC SATISFIED ASSERTION_1573, </TD></TR><BR>
<TR><TD>Z</TD><TD>CYP2B6 ISOPROPENYL CYP2B6 METHYL ADAMANTANE IS AN IN VITRO SELECTIVE INHIBITOR OF CYP2B6</TD><TD>BC SATISFIED ASSERTION_1538, </TD></TR><BR>
<TR><TD>Z</TD><TD>DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6</TD><TD>BC SATISFIED ASSERTION_669, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ZALEPLON IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_694, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF VORICONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_912, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF TRAZODONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1025, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_666, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RISPERIDONE IS HIGH</TD><TD>BC SATISFIED ASSERTION_495, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF RABEPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1091, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PANTOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_151, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF PALIPERIDONE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_628, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF NICARDIPINE IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_290, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIRTAZAPINE IS MEDIUM HIGH</TD><TD>BC SATISFIED ASSERTION_66, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF MIDODRINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_846, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LOVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_348, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF LANSOPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_762, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF INDOMETHACIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_678, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVOXAMINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_581, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUVASTATIN IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_674, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUPHENAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_894, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF FLUCONAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_420, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ESCITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_467, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF DILTIAZEM IS MEDIUM</TD><TD>BC SATISFIED ASSERTION_1220, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_664, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CITALOPRAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_1162, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF CHLORPROMAZINE IS LOW</TD><TD>BC SATISFIED ASSERTION_402, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATORVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_8, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ATOMOXETINE IS HIGH</TD><TD>BC SATISFIED ASSERTION_1063, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ARIPIPRAZOLE IS HIGH</TD><TD>BC SATISFIED ASSERTION_637, </TD></TR><BR>
<TR><TD>Z</TD><TD>BIOAVAILABILITY OF ALPRAZOLAM IS HIGH</TD><TD>BC SATISFIED ASSERTION_631, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZOLPIDEM IS 1.06e 4 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_813, ASSUMED EFFECTIVE DOSE OF ZOLPIDEM IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ZIPRASIDONE IS 1.0.1294e 4 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_698, ASSUMED EFFECTIVE DOSE OF ZIPRASIDONE IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VORICONAZOLE IS 4.66e 4 AT DOSE 0.6</TD><TD>BC SATISFIED ASSERTION_275, ASSUMED EFFECTIVE DOSE OF VORICONAZOLE IS 0.6, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF VENLAFAXINE IS 0.45.90.45e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_867, ASSUMED EFFECTIVE DOSE OF VENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF TRAZODONE IS 0.002 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_884, ASSUMED EFFECTIVE DOSE OF TRAZODONE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF THREOHYDROBUPROPION IS 5.098e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_267, ASSUMED EFFECTIVE DOSE OF THREOHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ROSUVASTATIN IS 1.88e 5 AT DOSE 0.01</TD><TD>BC SATISFIED ASSERTION_464, ASSUMED EFFECTIVE DOSE OF ROSUVASTATIN IS 0.01, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RISPERIDONE IS 7.9e 5 AT DOSE 0.001</TD><TD>BC SATISFIED ASSERTION_605, ASSUMED EFFECTIVE DOSE OF RISPERIDONE IS 0.001, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF RANOLAZINE IS 2.6e 4 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_541, ASSUMED EFFECTIVE DOSE OF RANOLAZINE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PERPHENAZINE IS 9.84e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_466, ASSUMED EFFECTIVE DOSE OF PERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF PANTOPRAZOLE IS 2.5e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1219, ASSUMED EFFECTIVE DOSE OF PANTOPRAZOLE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF OLANZAPINE IS 1.05e 5 AT DOSE 0.0125</TD><TD>BC SATISFIED ASSERTION_1232, ASSUMED EFFECTIVE DOSE OF OLANZAPINE IS 0.0125, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF METRONIDAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_655, ASSUMED EFFECTIVE DOSE OF METRONIDAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LOVASTATIN IS 7.8e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1017, ASSUMED EFFECTIVE DOSE OF LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF LANSOPRAZOLE IS 0.004 AT DOSE 2.0</TD><TD>BC SATISFIED ASSERTION_104, ASSUMED EFFECTIVE DOSE OF LANSOPRAZOLE IS 2.0, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF KETOCONAZOLE IS 0.002 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_594, ASSUMED EFFECTIVE DOSE OF KETOCONAZOLE IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF HYDROXYBUPROPION IS 0.001 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_1179, ASSUMED EFFECTIVE DOSE OF HYDROXYBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUVASTATIN IS 4.0.04e 4 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_806, ASSUMED EFFECTIVE DOSE OF FLUVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUPHENAZINE IS 2.0.012e 6 AT DOSE 0.012</TD><TD>BC SATISFIED ASSERTION_844, ASSUMED EFFECTIVE DOSE OF FLUPHENAZINE IS 0.012, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUOXETINE IS 5.5e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1023, ASSUMED EFFECTIVE DOSE OF FLUOXETINE IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF FLUCONAZOLE IS 0.007 AT DOSE 0.4</TD><TD>BC SATISFIED ASSERTION_514, ASSUMED EFFECTIVE DOSE OF FLUCONAZOLE IS 0.4, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ESCITALOPRAM IS 5.002e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1085, ASSUMED EFFECTIVE DOSE OF ESCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ERYTHROHYDROBUPROPION IS 1.457e 4 AT DOSE 0.3</TD><TD>BC SATISFIED ASSERTION_518, ASSUMED EFFECTIVE DOSE OF ERYTHROHYDROBUPROPION IS 0.3, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF DILTIAZEM IS 6.067e 5 AT DOSE 0.12</TD><TD>BC SATISFIED ASSERTION_455, ASSUMED EFFECTIVE DOSE OF DILTIAZEM IS 0.12, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLOZAPINE IS 5.64e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_921, ASSUMED EFFECTIVE DOSE OF CLOZAPINE IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CLARITHROMYCIN IS 0.00251 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_131, ASSUMED EFFECTIVE DOSE OF CLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CHLORPROMAZINE IS 0.1.79e 5 AT DOSE 0.1</TD><TD>BC SATISFIED ASSERTION_153, ASSUMED EFFECTIVE DOSE OF CHLORPROMAZINE IS 0.1, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF CELECOXIB IS 7.05e 5 AT DOSE 0.2</TD><TD>BC SATISFIED ASSERTION_788, ASSUMED EFFECTIVE DOSE OF CELECOXIB IS 0.2, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BUPROPION IS 1.44e 4 AT DOSE 0.15</TD><TD>BC SATISFIED ASSERTION_624, ASSUMED EFFECTIVE DOSE OF BUPROPION IS 0.15, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF BETA HYDROXY LOVASTATIN IS 1.19e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_423, ASSUMED EFFECTIVE DOSE OF BETA HYDROXY LOVASTATIN IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ATORVASTATIN IS 2.52e 4 AT DOSE 0.08</TD><TD>BC SATISFIED ASSERTION_629, ASSUMED EFFECTIVE DOSE OF ATORVASTATIN IS 0.08, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ASENAPINE IS 4.e 6 AT DOSE 0.005</TD><TD>BC SATISFIED ASSERTION_224, ASSUMED EFFECTIVE DOSE OF ASENAPINE IS 0.005, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ARIPIPRAZOLE IS 4.52e 4 AT DOSE 0.03</TD><TD>BC SATISFIED ASSERTION_865, ASSUMED EFFECTIVE DOSE OF ARIPIPRAZOLE IS 0.03, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF ALPRAZOLAM IS 0.003.7e 5 AT DOSE 0.003</TD><TD>BC SATISFIED ASSERTION_312, ASSUMED EFFECTIVE DOSE OF ALPRAZOLAM IS 0.003, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DIDEMETHYLCITALOPRAM IS 1.897e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_942, ASSUMED EFFECTIVE DOSE OF S DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF S DEMETHYLCITALOPRAM IS 1.40.047e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_101, ASSUMED EFFECTIVE DOSE OF S DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DIDEMETHYLCITALOPRAM IS 0.04.971e 6 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_1148, ASSUMED EFFECTIVE DOSE OF R DIDEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF R DEMETHYLCITALOPRAM IS 1.946e 5 AT DOSE 0.04</TD><TD>BC SATISFIED ASSERTION_741, ASSUMED EFFECTIVE DOSE OF R DEMETHYLCITALOPRAM IS 0.04, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF O DESMETHYLVENLAFAXINE IS 6.86e 4 AT DOSE 0.45</TD><TD>BC SATISFIED ASSERTION_49, ASSUMED EFFECTIVE DOSE OF O DESMETHYLVENLAFAXINE IS 0.45, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 7 HYDROXYPERPHENAZINE IS 5.09e 7 AT DOSE 0.004</TD><TD>BC SATISFIED ASSERTION_880, ASSUMED EFFECTIVE DOSE OF 7 HYDROXYPERPHENAZINE IS 0.004, </TD></TR><BR>
<TR><TD>Z</TD><TD>MAXIMUM IN VIVO CONCENTRATION OF 14 HYDROXYCLARITHROMYCIN IS 8.8e 4 AT DOSE 0.5</TD><TD>BC SATISFIED ASSERTION_1126, ASSUMED EFFECTIVE DOSE OF 14 HYDROXYCLARITHROMYCIN IS 0.5, </TD></TR><BR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZOLPIDEM '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ZIPRASIDONE '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VORICONAZOLE '0.6)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'VENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'TRAZODONE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'THREOHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ROSUVASTATIN '0.01)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RISPERIDONE '0.001)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'RANOLAZINE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'PANTOPRAZOLE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'OLANZAPINE '0.0125)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'METRONIDAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'LANSOPRAZOLE '2.0)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'KETOCONAZOLE '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'HYDROXYBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUPHENAZINE '0.012)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUOXETINE '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'FLUCONAZOLE '0.4)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ESCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ERYTHROHYDROBUPROPION '0.3)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'DILTIAZEM '0.12)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLOZAPINE '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CHLORPROMAZINE '0.1)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'CELECOXIB '0.2)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BUPROPION '0.15)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'BETA-HYDROXY-LOVASTATIN '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ATORVASTATIN '0.08)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ASENAPINE '0.005)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ARIPIPRAZOLE '0.03)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'ALPRAZOLAM '0.003)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'S-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DIDEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'R-DEMETHYLCITALOPRAM '0.04)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 'O-DESMETHYLVENLAFAXINE '0.45)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '7-HYDROXYPERPHENAZINE '0.004)</TD></TR>
<TR><TD>(ASSUMED-EFFECTIVE-DOSE-OF-1-IS-2 '14-HYDROXYCLARITHROMYCIN '0.5)</TD></TR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF ROSUVASTATIN IS LOW</TD><TD>BC SATISFIED ASSERTION_1047, </TD></TR><BR>
<TR><TD>Z</TD><TD>ORAL DOSE FRACTION ABSORBED OF CLARITHROMYCIN IS HIGH</TD><TD>BC SATISFIED ASSERTION_219, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF N DEMETHYLDESACETYL DILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF N DEMETHYLDESACETYL DILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF S WARFARIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF S WARFARIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALISKIREN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALISKIREN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ALOSETRON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ALOSETRON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF AMBRISENTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF AMBRISENTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF APREPITANT IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF APREPITANT IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATRASENTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ATRASENTAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF BUPROPION IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF BUPROPION IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CELECOXIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CELECOXIB IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CONIVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CONIVAPTAN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF CYCLOSPORINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF CYCLOSPORINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DABIGATRAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DABIGATRAN ETEXILATE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DABIGATRAN ETEXILATE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DARIFENACIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DARIFENACIN IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DASATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DASATINIB IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DESACETYLDILTIAZEM IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DESACETYLDILTIAZEM IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DIHYDROERGOTAMINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DIHYDROERGOTAMINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DRONEDARONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DRONEDARONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF DULOXETINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF DULOXETINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EFAVIRENZ IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EFAVIRENZ IS CYP2B6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EVEROLIMUS IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EVEROLIMUS IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF EZETIMIBE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF EZETIMIBE IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUTICASONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUTICASONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF FLUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF FLUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF IMATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IMATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF INDINAVIR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF INDINAVIR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF IRINOTECAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF IRINOTECAN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LAPATINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LAPATINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF LURASIDONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF LURASIDONE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MARAVIROC IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MARAVIROC IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF MELATONIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF MELATONIN IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NEBIVOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NEBIVOLOL IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF NILOTINIB IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF NILOTINIB IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PACLITAXEL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PACLITAXEL IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PANTOPRAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PANTOPRAZOLE IS CYP2C19, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PERPHENAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PERPHENAZINE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PHENYTOIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PHENYTOIN IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PIMOZIDE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PIMOZIDE IS CYP2D6, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PITAVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PITAVASTATIN IS OATP1B3, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF POSACONAZOLE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF POSACONAZOLE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF PRAVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUETIAPINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUETIAPINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF QUINIDINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF QUINIDINE IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RAMELTEON IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RAMELTEON IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF RANOLAZINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF RANOLAZINE IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSIGLITAZONE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSIGLITAZONE IS CYP2C8, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ROSUVASTATIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF ROSUVASTATIN IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SAXAGLIPTIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SAXAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SIMVASTATIN ACID IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SIMVASTATIN ACID IS OATP1B1, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF SITAGLIPTIN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF SITAGLIPTIN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TACRINE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TACRINE IS CYP1A2, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TALINOLOL IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TALINOLOL IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TICAGRELOR IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TICAGRELOR IS CYP3A4, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLBUTAMIDE IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLBUTAMIDE IS CYP2C9, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOLVAPTAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOLVAPTAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF TOPOTECAN IS METABOLIC CLEARANCE</TD><TD>PRIMARY TOTAL CLEARANCE ENZYME OF TOPOTECAN IS P GLYCOPROTEIN, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF PRAVASTATIN IS RENAL_EXCRETION</TD><TD>BC SATISFIED ASSERTION_645, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF KETOCONAZOLE IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_10, </TD></TR><BR>
<TR><TD>Z</TD><TD>PRIMARY TOTAL CLEARANCE MECHANISM OF ATORVASTATIN IS METABOLIC_CLEARANCE</TD><TD>BC SATISFIED ASSERTION_644, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_250, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1074, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY SIMVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_1034, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON BETA HYDROXY LOVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_438, </TD></TR><BR>
<TR><TD>Z</TD><TD>SOLE PK EFFECT OF ITRACONAZOLE ON ATORVASTATIN ALTER METABOLIC CLEARANCE</TD><TD>BC SATISFIED ASSERTION_134, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R CITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>R DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>R DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>S DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>S DIDEMETHYLCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CHLORPROMAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>DEMETHYLCITALOPRAM DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ESCITALOPRAM DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ESCITALOPRAM DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>HALOPERIDOL DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>HALOPERIDOL DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>LANSOPRAZOLE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>MIRTAZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>MIRTAZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OMEPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>OMEPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PANTOPRAZOLE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PRAVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>PRAVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ROSUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ROSUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIORIDAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIORIDAZINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>THIOTHIXENE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>THIOTHIXENE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TOPIRAMATE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>TOPIRAMATE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>VENLAFAXINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>VENLAFAXINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>AMIODARONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>AMIODARONE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BUPROPION DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>BUPROPION INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>FLUOXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PAROXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>PAROXETINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>SERTRALINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>SERTRALINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>TERBINAFINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>TERBINAFINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>QUINIDINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESVENLAFAXINE VIA CYP2D6</TD><TD>QUINIDINE INHIBITS CYP2D6, DESVENLAFAXINE IS NOT A SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ATORVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>ATORVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>BETA HYDROXY LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>CLOZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>CLOZAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUOXETINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>FLUOXETINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>FLUPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>FLUVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>FLUVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PACLITAXEL VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, PACLITAXEL IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>LOVASTATIN DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ROSIGLITAZONE VIA CYP2C8</TD><TD>LOVASTATIN DOES NOT INHIBIT CYP2C8, ROSIGLITAZONE IS SUBSTRATE OF CYP2C8, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PANTOPRAZOLE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, PANTOPRAZOLE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF SERTRALINE VIA CYP2C19</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C19, SERTRALINE IS SUBSTRATE OF CYP2C19, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF S WARFARIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, S WARFARIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CELECOXIB VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, CELECOXIB IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PHENYTOIN VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, PHENYTOIN IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TOLBUTAMIDE VIA CYP2C9</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP2C9, TOLBUTAMIDE IS SUBSTRATE OF CYP2C9, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF APREPITANT VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, APREPITANT IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CONIVAPTAN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CONIVAPTAN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF CYCLOSPORINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, CYCLOSPORINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DARIFENACIN VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DARIFENACIN IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DASATINIB VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DASATINIB IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DIHYDROERGOTAMINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DIHYDROERGOTAMINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DRONEDARONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, DRONEDARONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUTICASONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, FLUTICASONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF INDINAVIR VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, INDINAVIR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF LURASIDONE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, LURASIDONE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MARAVIROC VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, MARAVIROC IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUETIAPINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, QUETIAPINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF QUINIDINE VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, QUINIDINE IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>OLANZAPINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TICAGRELOR VIA CYP3A4</TD><TD>OLANZAPINE DOES NOT INHIBIT CYP3A4, TICAGRELOR IS SUBSTRATE OF CYP3A4, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF ALOSETRON VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, ALOSETRON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DULOXETINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, DULOXETINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF MELATONIN VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, MELATONIN IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RAMELTEON VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, RAMELTEON IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF TACRINE VIA CYP1A2</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP1A2, TACRINE IS SUBSTRATE OF CYP1A2, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>PERPHENAZINE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>PERPHENAZINE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>RISPERIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>RISPERIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF NEBIVOLOL VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, NEBIVOLOL IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PIMOZIDE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PIMOZIDE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF RISPERIDONE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, RISPERIDONE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF PERPHENAZINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, PERPHENAZINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUVOXAMINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUVOXAMINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF FLUOXETINE VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, FLUOXETINE IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF DESACETYLDILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, DESACETYLDILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>
<TR><TD>NO-PKI</TD><TD>ZIPRASIDONE DOES NOT INHIBIT THE METABOLIC CLEARANCE OF N DEMETHYLDESACETYL DILTIAZEM VIA CYP2D6</TD><TD>ZIPRASIDONE DOES NOT INHIBIT CYP2D6, N DEMETHYLDESACETYL DILTIAZEM IS SUBSTRATE OF CYP2D6, </TD></TR><BR>